Pentraxin-3 is a candidate biomarker on the spectrum of severity from pre-eclampsia to HELLP syndrome: GenPE study

Colmenares-Mejía, Claudia Carolina; Quintero-Lesmes, Doris Cristina; Bautista-Niño, Paula Katherine; Mahecha, Elizabeth Guio; Avendaño, Mónica Beltrán; Martínez, Luis; Serrano, Ricardo Ortiz; Leal, María Carolina Páez; Castro, Álvaro Monterrosa; Restrepo, Clara María Mesa; Monsalve, Germán; Sanín-Blair, Enrique; Saldarriaga, Wilmar; Luna, María Lucrecia; Casas, Juan P.; Díaz, Norma Cecilia Serrano

doi:10.1038/s41440-020-0434-0

Cited by 12 publications

(6 citation statements)

References 38 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Subsequently, the serum level of PTX3 reaches its highest level before delivery, and it is sharply decreased after delivery 27,28 . Recent studies have shown that PTX3 is involved in the pathogenesis of several vascular complications during pregnancy, and PTX3 levels are markedly elevated in women with preeclampsia, HELLP syndrome, intrauterine growth restriction, and pregnancy with type 1 diabetes or GDM and even in pregnant women with obesity 15,29–32 . Additionally, the expression of PTX3 is dramatically increased in placental tissues obtained from patients with unexplained recurrent pregnancy loss 16 .…”

Section: Discussionmentioning

confidence: 99%

“…27,28 Recent studies have shown that PTX3 is involved in the pathogenesis of several vascular complications during pregnancy, and PTX3 levels are markedly elevated in women with preeclampsia, HELLP syndrome, intrauterine growth restriction, and pregnancy with type 1 diabetes or GDM and even in pregnant women with obesity. 15,[29][30][31][32] Additionally, the expression of PTX3 is dramatically increased in placental tissues obtained from patients with unexplained recurrent pregnancy loss. 16 Collectively, we speculate that abnormally elevated levels of PTX3 can induce an aberrant innate immune response or exaggerate an inflammatory reaction, which leads to pathological pregnancy.…”

Section: F I G U R Ementioning

confidence: 99%

See 1 more Smart Citation

BMP2 suppresses the production of pentraxin 3 in human endometrial stromal and decidual stromal cells

Chang

Zhu

2022

The FASEB Journal

View full text Add to dashboard Cite

Bone morphogenetic protein 2 (BMP2) has been shown to act as a critical regulator in the processes of embryo implantation and endometrial decidualization. The expression and production of pentraxin 3 (PTX3) is essential for successful pregnancy, and aberrant production of PTX3 is involved in the pathogenesis of several vascular complications during pregnancy. Studies have shown that several transforming growth factor β superfamily members, including BMP2, can regulate female reproductive function by modulating the expression of PTX3 in human granulosa cells. However, to date, whether BMP2 can regulate the production of PTX3 during endometrial decidualization remains to be elucidated. In this study, we aimed to explore the effect of BMP2 on the expression and production of PTX3 and the underlying molecular mechanisms using immortalized human endometrial stromal cells (I‐HESCs) and human decidual stromal cells (HDSCs). We demonstrated that treatment with exogenous BMP2 significantly suppressed PTX3 production by decreasing the mRNA level of PTX3 in both I‐HESCs and HDSCs. The results also showed that BMP2 activated SMAD signaling by inducing an increase in the protein levels of phosphorylated SMAD1/5/8, and this effect could be abolished by pretreatment with the ALK2/3 inhibitor DMH‐1 but not with the ALK1/4/7 inhibitor SB431542. Additionally, combined knockdown of ALK2 and ALK3 completely reversed the BMP2‐induced suppressive effect on PTX3 expression, while concomitant knockdown of SMAD1 and SMAD5 or knockdown of SMAD4 completely reversed the BMP2‐induced suppressive effect on PTX3 expression. Taken together, these results indicate that BMP2 suppressed PTX3 production by decreasing PTX expression, which is mediated by a canonical ALK2/3‐mediated SMAD1/5‐SMAD4‐dependent signaling pathway. Our findings suggest that BMP2 may potentially regulate the process of endometrial decidualization by suppressing the production of PTX3 in humans.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: F I G U R Ementioning

confidence: 99%

BMP2 suppresses the production of pentraxin 3 in human endometrial stromal and decidual stromal cells

Chang

Zhu

2022

The FASEB Journal

View full text Add to dashboard Cite

show abstract

“…However, it is important to note that the predictive value of these serum biomarkers is only nine per cent for PE and relatively lower (~1.5%) for EOPE. Pentraxin 3 (PTX3), an inflammatory marker, is elevated at 11-14 wk in pregnant women who developed PE subsequently 31 . Similarly, asymmetric dimethylarginine is a metabolite (a competitive inhibitor of nitric oxide synthase with a key role in the pathophysiology of endothelial dysfunction), which increases in the first trimester in pregnant women who eventually developed EOPE 32 .…”

Section: Current Status Of Various Serum Biomarkers For Early Predict...mentioning

confidence: 99%

Early prediction of pre-eclampsia using circulating placental exosomes: Newer insights

Madan,

Rao,

Shinde

et al. 2023

Indian J Med Res

View full text Add to dashboard Cite

Pre-eclampsia (PE), a multifactorial de novo hypertensive pregnancy disorder, is one of the leading causes of foeto-maternal morbidity and mortality. Currently, antihypertensive drugs are the first-line therapy for PE and evidence suggests that low-dose aspirin initiated early in high risk pregnancies may reduce the risk of development or severity of PE. However, an early prediction of this disorder remains an unmet clinical challenge. Several potential serum biomarkers associated with maternal immunoregulation and placental angiogenesis have been evaluated but are ineffective and inconsistent for early prediction. Although placental biomarkers would be more specific and sensitive in predicting the risk of PE, accessing the placenta during pregnancy is not feasible. Circulating placental exosomes (pEXO), originating from foeto-maternal interface, are being evaluated as the placenta’s surrogate and the best source of non-invasive placental biomarkers. pEXO appear in the maternal circulation starting from six weeks of gestation and its dynamic biological cargo across pregnancy is associated with successful pregnancy outcomes. Therefore, monitoring changes in pEXO expression profiles could provide new insights into the prediction, diagnosis and treatment of PE. This narrative review comprehensively summarizes the available literature on the candidate predictive circulating biomarkers evaluated for PE to date. In particular, the review elucidates the current knowledge of distinct molecular signatures emanating from pEXO in pre-eclamptic women to support the discovery of novel early predictive biomarkers for effective intervention and management of the disease.

show abstract

“…Plasma cell-free DNA and human suppression of tumorigenesis served as diagnostic biomarkers for gestational hypertension (GH) and PE [ 16 ]. Pentraxin 3, an acute-phase protein which is produced and released in response to inflammatory stimuli, has been proposed as a novel biomarker predicting placental failure [ 17 ] and was also associated with PE [ 18 ]. Using an effective peptidomic analysis, Wakabayashi et al identified seven circulating HDP-associated peptides (P-2081, P-2091, P-2127, P-2209, P-2378, P-2858, and P-3156) and proposed them as biomarkers for the diagnosis of HDP [ 19 ].…”

Section: Predictionmentioning

confidence: 99%

Preeclampsia up to date—What’s going on?

Bokuda

Ichihara

2023

Hypertens Res

View full text Add to dashboard Cite

Preeclampsia is a hypertensive disorder in pregnancy characterized by placental malperfusion and subsequent multi-organ injury. It accounts for approximately 14% of maternal deaths and 10–25% of perinatal deaths globally. In addition, preeclampsia has been attracting attentions for its association with risks for developing chronic diseases in later life for both mother and child. This mini-review discusses on latest knowledge on prediction, prevention, management, and long-term outcomes of preeclampsia and also touches on association between COVID-19 and preeclampsia. HTN hypertension, HDP hypertensive disorders of pregnancy, PE preeclampsia, BP blood pressure, cfDNA cell-free DNA, ST2 human suppression of tumorigenesis 2, sFlt-1 soluble fms-like tyrosine kinase-1, PIGF placental growth factor, VEGF vascular endothelial growth factor, VEGFR VEGF receptor, TGF β transforming growth factor β , ENG endoglin, sENG soluble ENG, PRES posterior reversible encephalopathy syndrome, AKI acute kidney injury, CVD cardiovascular disease, ESKD end-stage kidney disease, ACE angiotensinogen converting enzyme, Ang angiotensin.

show abstract

Pentraxin-3 is a candidate biomarker on the spectrum of severity from pre-eclampsia to HELLP syndrome: GenPE study

Cited by 12 publications

References 38 publications

BMP2 suppresses the production of pentraxin 3 in human endometrial stromal and decidual stromal cells

BMP2 suppresses the production of pentraxin 3 in human endometrial stromal and decidual stromal cells

Early prediction of pre-eclampsia using circulating placental exosomes: Newer insights

Preeclampsia up to date—What’s going on?

Contact Info

Product

Resources

About